Clinical Report: Treatment Outcomes of FGFR Inhibitors in Advanced Gastric Cancer

Background

Gastric cancer is a leading cause of cancer-related mortality globally, with many patients diagnosed at advanced stages where treatment options are limited. FGFR2 amplification is associated with poor survival outcomes in gastric cancer.

Data Highlights

Key Findings

• FGFR2 amplification is linked to significantly worse survival in gastric cancer patients.
• Case 1 achieved a PFS of 4.4 months and OS of 8.3 months with pemigatinib.
• Case 2 achieved a PFS of 5.7 months and OS of 18.5 months with infigratinib.
• Both patients experienced manageable adverse events related to FGFR inhibitors.

Clinical Implications

The findings suggest that FGFR inhibitors could be a viable treatment option for advanced gastric cancer patients with FGFR2 amplification, particularly for those who cannot tolerate standard therapies. Clinicians should consider next-generation sequencing to identify suitable candidates for FGFR-targeted therapy.

Conclusion

This case series indicates the potential efficacy of FGFR inhibitors in advanced gastric cancer with FGFR2 amplification, warranting further investigation in larger cohorts.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. The ASCO Post, 2025 -- Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
3. PubMed, 2026 -- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
4. the asco post — Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
5. The ASCO Post — FGFR2 Inhibitor Infigratinib Active in Chemotherapy-Refractory Cholangiocarcinoma
6. Global prevalence of FGFR2b protein overexpression in advanced gastric cancer
7. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update - PubMed
8. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial - PMC